Trial Profile
An open-label, randomized, phase II trial of cetuximab with or without PX-866 in patients with relapsed or metastatic head and neck squamous cell cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2015
Price :
$35
*
At a glance
- Drugs Sonolisib (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Oncothyreon
- 30 Sep 2015 The addition of PX-866 to cetuximab failed to improve PFS, ORR, or OS in patients with relapsed or metastatic head and neck squamous cell cancer
- 29 Sep 2015 New trial record